Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
European Commission · Horizon Europe
See all 418 calls from European Commission →- Funder
- European Commission · Horizon Europe
- Award amount
- €8,000,000 – €10,000,000
- Deadline
- February 17, 2027
- Eligible countries
- European Union, United Kingdom, Norway, Iceland, Switzerland, Israel, Global
Summary
Open EU call topic HORIZON-HLTH-2027-01-CARE-02 · HORIZON Research and Innovation Actions. Part of call HORIZON-HLTH-2027-01: Cluster 1 - Health (Single stage - 2027/1). Next deadline 2027-02-17. Topic page: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-CARE-02
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products[1]) and enhanced health outcomes by ensuring safer and more effective use of medication. - Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. - Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines. - Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence. - Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs.
Scope: While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. On average, 16% of hospitalised older[2] patients experience significant ADRs, varying in…
Summary as listed by the funder. Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement →What European Union reviewers look for
- Most Horizon Europe calls score three criteria (the ERC uses excellence alone). Excellence: clarity and ambition of the objectives, and the soundness of the methodology.
- Impact: credible pathways to the expected outcomes, and measures to communicate and exploit results.
- Quality and efficiency of implementation: the work plan, resources and the consortium's capacity.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free